EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status

Jane Gibson iD, Reuben J Pengelly, Amatta Mirandari, Konstantinos Boukas, Sophia Stanford, Thomas Desmond Cecil, Faheez Mohamed, Sanjeev Paul Dayal, Alexios Tzivanakis, Brendan John Moran, Alex Mirnezami, Norman John Carr und 1 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jane Gibson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Pseudomyxoma Peritonei, GTP-Binding Protein alpha Subunits, Gs, Chromogranins, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pelican Cancer Foundation, Mesothelioma uk, Peritoneal Malignancy Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Pseudomyxoma peritonei (PMP) is an unusual condition with unique behaviour caused by a mucinous neoplasm, usually arising from the appendix. The aim of this study was to evaluate the prevalence of genomic alterations in clinical specimens of PMP using a targeted assay and correlate the findings with clinical, pathological and outcome data. Sequencing data from 223 patients were analysed.

Results

The median follow‐up interval was 48 months. The primary neoplasm was appendiceal in 216 patients, ovarian in 4, urachal in 2 and renal in one. We confirmed common mutations in GNAS and KRAS (42% each) with significant co‐occurrence of variants in these genes. TP53 mutations were found in 8%. Other mutations were rare but included novel mutations in BAP1 and ERBB4 . Of 17 patients with acellular peritoneal mucin, 6 (35%) were positive for DNA mutations. The non‐appendiceal cases generally showed a similar mutational landscape to the appendiceal lesions with GNAS and KRAS commonly mutated, although one urachal lesion showed multi‐hit TP53 mutation without variants in either GNAS or KRAS . Survival was significantly associated with the grade of the primary neoplasm, the grade of the peritoneal disease, the completeness of cytoreduction score and with mutation in either GNAS , KRAS or both. The hazard ratio (HR) associated with mutation in GNAS and/or KRAS was 1.87 ( p = 0.004).

Conclusions

Survival outcome was more closely associated with the grade of the peritoneal disease than with the grade of the primary neoplasm. Our findings support the developing concept that mutational analysis may provide prognostic information in patients with PMP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomyxoma PeritoneiGTP-Binding Protein alpha Subunits, GsChromograninsCytoreduction Surgical ProceduresProto-Oncogene Proteins p21(ras)MutationPeritoneal NeoplasmsHyperthermic Intraperitoneal ChemotherapyHumansFemaleMiddle AgedMaleAgedAdultAged, 80 and overYoung AdultPrognosisCombined Modality Therapy

Substanzen

GTP-Binding Protein alpha Subunits, GsChromograninsGNAS protein, humanProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Bio-R Bioinformatics Research Facility, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Wessex Investigational Sciences Hub, Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK.

ORCID-Profile: Jane Gibson

Förderung

  • Pelican Cancer Foundation
  • Mesothelioma uk
  • Peritoneal Malignancy Institute

Zitieren

APA

Gibson, J., Pengelly, R. J., Mirandari, A., Boukas, K., Stanford, S., Cecil, T. D., Mohamed, F., Dayal, S. P., Tzivanakis, A., Moran, B. J., Mirnezami, A., Carr, N. J., & Ennis, S. (2024). Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status. Cancer Medicine. https://doi.org/10.1002/cam4.70340

Vancouver

Gibson J, Pengelly RJ, Mirandari A, Boukas K, Stanford S, Cecil TD, et al. Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status. Cancer Medicine. 2024. doi:10.1002/cam4.70340

BibTeX
@article{Gibson2024,
  author = {Gibson, Jane and Pengelly, Reuben J and Mirandari, Amatta and Boukas, Konstantinos and Stanford, Sophia and Cecil, Thomas Desmond and Mohamed, Faheez and Dayal, Sanjeev Paul and Tzivanakis, Alexios and Moran, Brendan John and Mirnezami, Alex and Carr, Norman John and Ennis, Sarah},
  title = {Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70340}
}
Kostenlos starten →